The Supreme Court unanimously rejected an attempt to significantly restrict access to a key abortion medication, mifepristone, on Thursday. The conservative majority ruled that the antiabortion physicians who filed the case did not have standing to challenge the Food and Drug Administration’s approval of the drug.

In a written opinion for the court, Justice Brett M. Kavanaugh said that because the plaintiffs don’t prescribe, sell or manufacture mifepristone, they suffer no direct monetary injuries related to the FDA’s loosening regulations for obtaining the drug in 2016 and 2021.

“We now know that patients and clinicians across the country will continue to have access to mifepristone for medication abortion and miscarriage management,” Stella Dantas, president of the American College of Obstetricians and Gynecologists, said in a statement. “Decades of clinical research have proven mifepristone to be safe and effective, and its strong track record of millions of patient uses confirms that data.”

Here’s what you need to know.

ncG1vNJzZmivp6x7uK3SoaCnn6Sku7G70q1lnKedZLWmrcutn2hqYGeBcHyVaGhsZ5GXvLPAyKilZqiZoblurcKcnKyrXaK2p7HPq6CsrJ%2BjsnA%3D